# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 08-08-2024 | 06-30-2024 | 10-Q | |
2 | 05-08-2024 | 03-31-2024 | 10-Q | |
3 | 02-28-2024 | 12-31-2023 | 10-K |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancerBrenetafu...
Cantor Fitzgerald analyst Eric Schmidt reiterates Immunocore Hldgs (NASDAQ:IMCR) with a Overweight.
Di Donato has accepted the role of Chief Executive Officer at a private, early-stage biotech headquartered in San Diego, Califo...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Immunocore Hldgs (NASDAQ:IMCR) with a Buy and maintains $100 pri...
Oppenheimer analyst Jeff Jones reiterates Immunocore Hldgs (NASDAQ:IMCR) with a Outperform and raises the price target from ...
Needham analyst Gil Blum reiterates Immunocore Hldgs (NASDAQ:IMCR) with a Buy and maintains $81 price target.
Immunocore Hldgs (NASDAQ:IMCR) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0....